Autolus Therapeutics

Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

All edits

Edits on 26 March, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 26 March, 2020 7:10 pm
Edits made to:
Infobox (+1 properties)

Infobox

Total funding amount (USD)
80,000,000
Edits on 18 September, 2019
Golden AI
Golden AI edited on 18 September, 2019 10:15 pm
Edits made to:
Infobox (+1 properties)
Edits on 6 September, 2019
Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 6 September, 2019 9:29 pm
Edits made to:
Article (+4/-4 characters)

Article

Autolus is developing AUTO1, a programmed T cell therapy targeting CD19CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.

Meredith Hanel
Meredith Hanel edited on 6 September, 2019 2:29 pm
Edits made to:
Timeline (+22 characters)
Further reading (+1 rows) (+5 cells) (+189 characters)

Further reading

Title
Author
Link
Type
Date

New CAR T-cell therapy for leukemia associated with fewer harmful side effects

Henry Killworth

Web

September 4, 2019

Timeline

September 2, 2019

Nature Medicine (2019)

Meredith Hanel
Meredith Hanel edited on 6 September, 2019 2:25 pm
Edits made to:
Timeline (+1 events) (+284 characters)
Article (+338 characters)

Article

Pre-clinical and clinical data from an ongoing Phase I CARPALL trial of AUTO1 were published in Nature Medicine in 2019. In the Phase I clinical trial 86% of the pediatric ALL patients (n=14) showed molecular complete remission after a single dose with a median duration of remission of 7.4 months and no severe cytokine release syndrome.

Timeline

September 2, 2019

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Authors from Autolus and various cancer research institutes in London, UK presented pre-clinical and clinical data on the programmed T cell therapy called AUTO1.

Meredith Hanel
Meredith Hanel edited on 6 September, 2019 2:07 pm
Edits made to:
Article (+1360 characters)

Article

T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes. The company has a collaboration partnership with AbCellera Biologics Inc. for a project in antibody discovery.

Pipeline and products

Autolus is developing AUTO1, a programmed T cell therapy targeting CD19 to treat acute lymphoblastic B cell leukemia (ALL). The therapy designed to reduce the risk of severe cytokine release syndrome, is in a Phase I clinical trial as of 2019. Cytokine release syndrome is a condition that can occur after immunotherapy threatment and that can be life threatening. The therapy can cause immune cells to release a large release of cytokines into the blood and lead to symptoms like fever, nausea, headache, rask, rapid hearbeat, low blood pressure and trouble breathing. AUTO1 uses a novel CD19 binder that allows rapid disengagement of CAR T cells after target cell encounter and kill.

AUTO2 is a programmed T cell therapy with two targets, for the treatment of relapsed or refractory multiple myeloma. AUTO2 is in PhaseI/II clinical trials as of 2019.

AUTO3 is a dual-targeting programmed T cell therapy for treating relapsed or refractory diffuse large B-cell lymphoma, which is in Phase I/II clinical trials as of 2019.

AUTO4 is a programmed T cell therapy for treatment of peripheral T-cell lymphoma and is in Phase I/II clinical trials as of 2019.

AUTO6 is a programmed T cell therapy for treatment of neuroblastoma.

Meredith Hanel
Meredith Hanel edited on 6 September, 2019 1:36 pm
Edits made to:
Topic thumbnail

Autolus Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Edits on 25 April, 2019
Golden AI
Golden AI edited on 25 April, 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 30 March, 2019
Dawson Sewell
Dawson Sewell edited on 30 March, 2019 6:20 pm
Edits made to:
Infobox (+4 properties)
Edits on 15 March, 2019
Dawson Sewell
Dawson Sewell edited on 15 March, 2019 6:42 pm
Edits made to:
Infobox (+11 properties)
Article (+48/-48 characters)
Further reading (+3 rows) (+12 cells) (+775 characters)
Documentaries, videos and podcasts (+1 rows) (+3 cells) (+101 characters)
Categories (+2 topics)
Related Topics (+2/-2 topics)

Article

Autolus develops and commercializes engineered T-cell immunotherapyimmunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.

...

T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recogniserecognize and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen ReceptorsChimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes.

Further reading

Title
Author
Link
Type

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

Autolus Therapeutics plc

Web

Biotech to create 170 jobs, invest $28M in new Rockville HQ

Katie Arcieri

Web

Documentaries, videos and podcasts

Title
Date
Link

Cell Therapy Commercialization in Oncology

January 8, 2019

Infobox

Categories

Related Topics

Edits on 10 January, 2019
Meredith Hanel
Meredith Hanel edited on 10 January, 2019 5:47 pm
Edits made to:
Description (+224 characters)
Article (+805 characters)
People (+5 rows) (+10 cells) (+178 characters)
Related Topics (+2 topics)
Topic thumbnail

Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Article

Autolus develops and commercializes engineered T-cell immunotherapy products to treat cancer. Autolus supplies engineering chimeric antigen receptors (CAR) T-cell products that kill malignant cells and protect from malignancy in the long-term. The company provides T-cell products for hematological and solid tumors.

...

T-cells normally detect and eliminate abnormal or cancerous cells in the body but sometimes cells escape detection and develop into tumors. Autolus programs T-cells to recognise and destroy tumour cells by transferring a gene into T-cells so they express Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) that recognize targets on the surface of malignant cells. For their process Autolus uses their own proprietary viral vector and semi-automated cell manufacturing processes.

People

Name
Role
Related Golden topics

Dr. Christian Martin Itin

Chairman, CEO

Dr. Jim Faulkner, PhD

Head of Manufacturing

Dr. Louise Holliday

Head of Intellectual Property

Dr. Martin Pulé

Founder, CSO

Mr. Christopher Vann

COO

Related Topics

Edits on 25 July, 2018
Melanie Manipula
Melanie Manipula edited on 25 July, 2018 12:16 am
Edits on 20 April, 2018
Melanie Manipula
Melanie Manipula edited on 20 April, 2018 11:38 pm
Edits made to:
Topic thumbnail

Autolus Therapeutics

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

Melanie Manipula"Initial topic creation"
Melanie Manipula created this topic on 20 April, 2018 11:34 pm
Edits made to:
Description
Academic papers
People
Further reading
Documentaries, videos and podcasts
Companies
Products
Topic thumbnail

 Autolus

Autolus is a biopharmaceutical company focused on programmed T-cell therapies for treatment of cancer. Autolus was founded in 2014 and is based in London, UK. Autolus Limited is a subsidiary of Autolus Holdings (UK) Limited.

No more activity to show.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.